FDA Approves Probuphine Implant for Opioid Dependence

Share this content:
FDA Approves Probuphine Implant for Opioid Dependence
FDA Approves Probuphine Implant for Opioid Dependence

THURSDAY, May 26, 2016 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first-ever buprenorphine implant to treat opioid dependence, the agency said Thursday in a news release.

Up to now, the drug buprenorphine has only been available in pill or film form to be placed under a person's tongue, the FDA said. Probuphine, which provides a constant, low-level dose of the drug, is designed to last six months. The drug, combined with behavioral therapy, can combat opioid addiction without "causing the cycle of highs and lows associated with opioid misuse or abuse," and can make the addictive qualities of opioid use less attractive, the FDA said. The agency cited U.S. government statistics that opioid addicts receiving this combined therapy cut their risk of death from all causes by half.

Probuphine's four one-inch rods are surgically implanted under the skin of the upper arm. If additional treatment is needed, a second set of rods may subsequently be implanted in the opposite arm. Sixty-three percent of people who used Probuphine had no evidence of illicit opioid use throughout the six months of treatment, the agency said.

The label includes a boxed warning of potential dangers during the product's insertion or removal, the FDA said. These include the potential risks of implant protrusion and nerve damage.

Probuphine is marketed by San Francisco-based Titan Pharmaceuticals and Princeton, N.J.-based Braeburn Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NTproBNP Levels Are Significantly Lower in Blacks

NTproBNP Levels Are Significantly Lower in Blacks

Higher NTproBNP levels linked to increased risk of death; this association did not differ by race

Data May Weigh on Pros/Cons of Expanded Care Optometry

Data May Weigh on Pros/Cons of Expanded Care ...

Majority of residents in Kentucky, Oklahoma, New Mexico live within 30 minutes of ophthalmologist

Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

Gaps Seen Between Hearing Loss, Receipt of Medical ...

About 20.6 percent of those with hearing less than excellent/good had visited doctor for hearing issues

is free, fast, and customized just for you!

Already a member?

Sign In Now »